Biogen CEO Says New Drugs Offset MS Decline, Eyes 2026 “Transformational Era” at JPMorgan Conference

Biogen logo Key Points Biogen's recent launches in Alzheimer’s, Friedreich’s ataxia, postpartum depression and ALS are now offsetting MS decline, with those growth drivers up 53% and contributing about $1.9 billion. Management completed a structural cost reset—about $1 billion in gross and $800 million net savings with ~15% headcount reduction and 26% lower R&D—while tightening portfolio discipline and reporting 10 Phase III programs and five potential new products. CEO Chris Viehbacher called 2026 ...